Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 16, Issue 3, Pages 257-271
Publisher
Future Medicine Ltd
Online
2015-02-25
DOI
10.2217/pgs.14.133
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).:
- (2014) José Baselga et al. CANCER RESEARCH
- Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
- (2014) Vikram B. Wali et al. MOLECULAR CANCER RESEARCH
- HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients
- (2013) Soo Youn Bae et al. BREAST CANCER RESEARCH AND TREATMENT
- HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
- (2013) Allan Lipton et al. BREAST CANCER RESEARCH AND TREATMENT
- RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
- (2013) C. Mirschberger et al. CANCER RESEARCH
- An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
- (2013) A. P. Garner et al. CANCER RESEARCH
- Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2013) P. LoRusso et al. CLINICAL CANCER RESEARCH
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Functional cooperation of miR-125a, miR-125b and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
- (2013) S Wang et al. Cell Death & Disease
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) F. Cardoso et al. ANNALS OF ONCOLOGY
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis
- (2012) H. Lahlou et al. CANCER RESEARCH
- HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
- (2012) D. B. Vaught et al. CANCER RESEARCH
- Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
- (2012) J. T. Garrett et al. CLINICAL CANCER RESEARCH
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
- (2012) M. J. Higgins et al. CLINICAL CANCER RESEARCH
- 382 Preclinical Pharmacokinetics of GE-huMab-HER3, a Novel Humanized, Glycoengineered Anti-HER3 Antibody Using PHER3/HER3 Ratio as Pharmacodynamics (PD) Marker
- (2012) G. Meneses-Lorente et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Small-Animal SPECT/CT of HER2 and HER3 Expression in Tumor Xenografts in Athymic Mice Using Trastuzumab Fab-Heregulin Bispecific Radioimmunoconjugates
- (2012) E. J. Razumienko et al. JOURNAL OF NUCLEAR MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling
- (2012) Q. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Detection of HER2 amplification in circulating free DNA in patients with breast cancer
- (2011) K Page et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
- (2011) Xiaoping Huang et al. CANCER LETTERS
- Abstract P6-15-15: MM-111 - A Novel Bispecific Antibody Targeting HER-2/HER-3 Z Heterodimer: Safety and Tolerability in a First-In Human Phase I/II Study in Patients with Refractory HER2-Positive (HER-2+) Cancers
- (2011) M Beeram et al. CANCER RESEARCH
- Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
- (2011) R. Ghosh et al. CANCER RESEARCH
- Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer
- (2011) Sietske B.M. Gaykema et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival
- (2010) Connie G. Chiu et al. ANNALS OF SURGERY
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
- (2010) Norma O’Donovan et al. INVESTIGATIONAL NEW DRUGS
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
- (2009) X. Huang et al. CANCER RESEARCH
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
- (2009) Evandro de Azambuja et al. Targeted Oncology
- Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
- (2008) M K Robinson et al. BRITISH JOURNAL OF CANCER
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition
- (2008) Rebecca S. Muraoka-Cook et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer
- (2008) Frank E. Jones JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Systems-Level Analysis of ErbB4 Signaling in Breast Cancer: A Laboratory to Clinical Perspective
- (2008) C.-P. Chuu et al. MOLECULAR CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started